Most Read

Johnson & Johnson Innovation facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function. To date, Morphic

Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv

HTL0030310 is a potent and selective agonist of the SSTR5 (somatostatin 5) receptor and the sixth molecule designed by the Company using its GPCR Structure-Based Drug Design (SBDD)

The financing was led by RA Capital Management and was joined by new investors including Eventide Asset Management, Biotechnology Value Fund, OrbiMed, EcoR1 Capital, Vida Ventures, Curative Ventures

The patent (U.S. Patent Number 10206894) covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts. The new patent broadens the Company’s

“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president,

Under the collaboration, the firms will evaluate the safety and tolerability of the combination therapy of Innovent’s Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death

Under the agreement, Knight will initially lend Moksha8 up to US $25 million in working capital funding, of which US $10 million will be issued at closing. Knight

PROVENGE (sipuleucel-T) was the first U.S. Food and Drug Administration (FDA)-approved immunotherapy made from a patient’s own immune cells. “We are pleased to work with Dendreon on this